Logo image of MRVL.CA

MARVEL BIOSCIENCES CORP (MRVL.CA) Stock Fundamental Analysis

TSX-V:MRVL - TSX Venture Exchange - CA57384M1077 - Common Stock - Currency: CAD

0.15  0 (0%)

Fundamental Rating

0

Overall MRVL gets a fundamental rating of 0 out of 10. We evaluated MRVL against 0 industry peers in the Unkown industry. MRVL has a bad profitability rating. Also its financial health evaluation is rather negative. MRVL is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MRVL has reported negative net income.
In the past year MRVL has reported a negative cash flow from operations.
MRVL had negative earnings in each of the past 5 years.
In the past 5 years MRVL always reported negative operating cash flow.
MRVL.CA Yearly Net Income VS EBIT VS OCF VS FCFMRVL.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -1M -2M -3M

1.2 Ratios

Industry RankSector Rank
ROA -616.67%
ROE N/A
ROIC N/A
ROA(3y)-318.74%
ROA(5y)-216.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRVL.CA Yearly ROA, ROE, ROICMRVL.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MRVL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRVL.CA Yearly Profit, Operating, Gross MarginsMRVL.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

0

2. Health

2.1 Basic Checks

MRVL has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MRVL has been increased compared to 5 years ago.
Compared to 1 year ago, MRVL has a worse debt to assets ratio.
MRVL.CA Yearly Shares OutstandingMRVL.CA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
MRVL.CA Yearly Total Debt VS Total AssetsMRVL.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

2.2 Solvency

MRVL has an Altman-Z score of -86.62. This is a bad value and indicates that MRVL is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -86.62
ROIC/WACCN/A
WACCN/A
MRVL.CA Yearly LT Debt VS Equity VS FCFMRVL.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 1M -1M 2M -2M

2.3 Liquidity

MRVL has a Current Ratio of 0.14. This is a bad value and indicates that MRVL is not financially healthy enough and could expect problems in meeting its short term obligations.
MRVL has a Quick Ratio of 0.14. This is a bad value and indicates that MRVL is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14
MRVL.CA Yearly Current Assets VS Current LiabilitesMRVL.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 45.57% over the past year.
EPS 1Y (TTM)45.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.34%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MRVL.CA Yearly Revenue VS EstimatesMRVL.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024
MRVL.CA Yearly EPS VS EstimatesMRVL.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRVL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRVL.CA Price Earnings VS Forward Price EarningsMRVL.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRVL.CA Per share dataMRVL.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.02 -0.04 -0.06

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRVL!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MARVEL BIOSCIENCES CORP

TSX-V:MRVL (2/21/2025, 7:00:00 PM)

0.15

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)06-24 2024-06-24
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners15.23%
Ins Owner ChangeN/A
Market Cap6.72M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.03
FCFYN/A
OCF(TTM)-0.03
OCFYN/A
SpS0
BVpS-0.07
TBVpS-0.07
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -616.67%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-318.74%
ROA(5y)-216.35%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z -86.62
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)45.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.34%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y57.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y47.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y47.1%
OCF growth 3YN/A
OCF growth 5YN/A